Melatonin Receptors as Novel Targets to Treat Mood Disorders
Psychiatric disorders, particularly in older adults, are often associated with insomnia, early morning awakenings, desynchronization of circadian rhythms and neurochemical dysfunction.Melatonin promote sleep, entrains circadian rhythms, and modulates neurochemical responses through activation of two G-protein coupled melatonin receptors, the MT1 and MT2.This presentation will review the mechanisms involved in the regulation and signaling of the MT1 and MT2 melatonin receptors, and their role as targets for the treatment of mood disorders using novel melatonin ligands, including those currently used in humans (e.g., agomelatine).
Margarita L.Dubocovich
Department of Pharmacology,SUNY Buffalo, New York, USA
国内会议
山东泰安
英文
132-132
2016-09-23（万方平台首次上网日期，不代表论文的发表时间）